CoChat

Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

Open access
Kostine, Marie, Mauric, Eleonora, Tison, Alice, Barnetche, Thomas, Barre, Aurélien, Nikolski, Macha, Rouxel, Léa, Dutriaux, Caroline, Dousset, Léa, Prey, Sorilla, Beylot-Barry, Marie, Seneschal, Julien, Veillon, Rémi, Vergnenegre, Charlotte, Daste, Amaury, Domblides, Charlotte, Sionneau, Baptiste, Gross-Goupil, Marine, Ravaud, Alain, Forcade, Edouard, Schaeverbeke, Thierry · 2021 · European Journal of Cancer
Cited by 101

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

PURPOSE: As gut microbiota composition is an important determinant of response to immune checkpoint inhibitors (ICIs), we examined the effect of various co-medications known for their interaction with microbiota, when given at ICI initiation. PATIENTS AND METHODS: We identified patients with advanced cancer treated with ICI between May 2015 and September 2017 in our institution. Co-medications given within 1 month before or 1 month after the first administration of ICI were reviewed from medical records. Survival data were analysed with univariable Cox regression, and the combined effect of multiple factors was assessed with factor analysis of mixed data (FAMD). The impact of co-medications on immune-related adverse events (irAEs) occurrence was also assessed. RESULTS: A total of 635 patients were included. Psychotropic drugs (41%), proton pump inhibitors (PPIs; 38%), angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin II receptor blockers (ARBs; 32%), glucocorticoids (26%), antibiotics (24%), statins (21%) and morphine (20%) were the most prescribed co-medications. Baseline use of antibiotics, glucocorticoids >10 mg/day, PPIs, psychotropic drugs, morphine and insulin was associated with significantly shortened overall survival and decreased tumour response, whereas coadministration of statins, ACEs and/or ARBs, non-steroidal anti-inflammatory drugs, aspirin and oral antidiabetic drugs did not impact patient outcomes. Treatments that altered the response to ICI were also associated with a decreased incidence of irAEs. FAMD revealed the respective weight of each factor or co-medication on the oncological outcomes. CONCLUSION: Co-medications must be carefully assessed at the time of ICI initiation and clinicians aware of their possible deleterious effect, notably for PPIs, glucocorticoids, antibiotics and psychotropic drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2021.08.036

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 101

Metadata

Authors
Kostine, M., Mauric, E., Tison, A., Barnetche, T., Barre, A., Nikolski, M., Rouxel, L., Dutriaux, C., Dousset, L., Prey, S., Beylot-Barry, M., Seneschal, J., Veillon, R., Vergnenegre, C., Daste, A., Domblides, C., Sionneau, B., Gross-Goupil, M., Ravaud, A., Forcade, E., & Schaeverbeke, T.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2021-11
Volume
157
Pages
474-484
ISSN
0959-8049 (ISSN-L)
OpenAlex
W3204988028
Cited by
101
References
21
FWCI
5.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. https://app.cochat.ai/papers/10.1016/j.ejca.2021.08.036
The paper
Kostine, M., Mauric, E., Tison, A., Barnetche, T., Barre, A., Nikolski, M., Rouxel, L., Dutriaux, C., Dousset, L., Prey, S., Beylot-Barry, M., Seneschal, J., Veillon, R., Vergnenegre, C., Daste, A., Domblides, C., Sionneau, B., Gross-Goupil, M., Ravaud, A., . . . Schaeverbeke, T. (2021). Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2021.08.036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.